Related Experiment Video

Updated: Oct 15, 2026

Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice
08:52

Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice

Published on: February 22, 2019

Progress toward the development of a vaccine to prevent Moraxella (Branhamella) catarrhalis infections

J C McMichael1

  • 1Wyeth-Lederle Vaccines, 211 Bailey Road, West Henrietta, NY 14586-9728, USA.

Microbes and Infection
|June 24, 2000
PubMed

Insights

Developing vaccines against Moraxella catarrhalis, a common cause of respiratory infections and otitis media, is progressing. Researchers are evaluating promising antigens for future clinical testing.

Area of Science:

  • Microbiology
  • Immunology
  • Vaccinology

Background:

  • Moraxella catarrhalis is a significant human pathogen.
  • It is a primary cause of otitis media and respiratory tract infections.
  • Current vaccine development is focused on identifying effective antigens.

Purpose of the Study:

  • To review promising antigens for Moraxella catarrhalis vaccine development.
  • To identify key targets for therapeutic intervention.

Main Methods:

  • Literature review of Moraxella catarrhalis antigens.
  • Analysis of potential vaccine candidates.

Main Results:

  • Several promising antigens have been identified, including 200K protein, hemagglutinins, lactoferrin-binding proteins, UspA proteins, CopB protein, transferrin-binding proteins, CD protein, E protein, and lipooligosaccharide conjugates.
  • These antigens represent potential targets for vaccine development.

Conclusions:

  • The identified antigens show promise for Moraxella catarrhalis vaccine development.
  • Clinical trials for some of these antigens are anticipated in the near future.

More Related Videos

The Utilization of Oropharyngeal Intratracheal PAMP Administration and Bronchoalveolar Lavage to Evaluate the Host Immune Response in Mice12:27

The Utilization of Oropharyngeal Intratracheal PAMP Administration and Bronchoalveolar Lavage to Evaluate the Host Immune Response in Mice

Published on: April 2, 2014

Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice06:32

Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice

Published on: September 19, 2016

Related Concept Videos

Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...